ANI Pharmaceuticals, Inc. Revenue 2009–2025
ANI Pharmaceuticals, Inc. reported $883.37M of revenue for fiscal 2025. That was 43.8% higher than fiscal 2024. Compared with fiscal 2020, the change was +323.7%.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $883.37M | +43.8% |
| FY 2024 | $614.38M | +26.2% |
| FY 2023 | $486.82M | +53.9% |
| FY 2022 | $316.38M | +46.4% |
| FY 2021 | $216.14M | +3.7% |
| FY 2020 | $208.47M | +0.9% |
| FY 2019 | $206.55M | +2.5% |
| FY 2018 | $201.58M | +14.0% |
| FY 2017 | $176.84M | +37.5% |
| FY 2016 | $128.62M | +68.5% |
| FY 2015 | $76.32M | +36.4% |
| FY 2014 | $55.97M | +86.1% |
| FY 2013 | $30.08M | +47.7% |
| FY 2012 | $20.37M | +4581.3% |
| FY 2011 | $435,160 | -82.4% |
| FY 2010 | $2.47M | +96.7% |
| FY 2009 | $1.26M | — |
Source: ANI Pharmaceuticals, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open ANIP 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
ANI Pharmaceuticals, Inc. reported $883.37M of revenue for fiscal 2025. That was 43.8% higher than fiscal 2024. Compared with fiscal 2020, the change was +323.7%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for ANI Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeANI Pharmaceuticals, Inc. — frequently asked questions
What is ANI Pharmaceuticals, Inc.'s revenue?
ANI Pharmaceuticals, Inc. (ANIP) reported revenue of $883.37M for fiscal year 2025, per its SEC filings.
How has ANI Pharmaceuticals, Inc.'s revenue changed over time?
Between fiscal 2009 and 2025, ANIP's revenue grew at roughly 50.6% per year (compound annual rate), from $1.26M to $883.37M.
Where does this data come from?
Figures are computed from ANI Pharmaceuticals, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.